|
Maya's Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
AI-generated briefing: Novartis and Bristol Myers Squibb pause CAR-T trials, Revolution Medicines wins pancreatic cancer approval, and Mendus advances cellular immunotherapy programs.
The top 10 stories from Wed Sep 2, 2026 06:59 AM to Thu Sep 3, 2026 06:59 AM
Generated September 3, 2026 at 6:59 AM
|
|
|
#1 Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC Published 2026-09-02 Akeso said ivonescimab met the overall-survival key secondary endpoint in an interim Phase III HARMONi-2 analysis, outperforming pembrolizumab in first-line PD-L1-positive NSCLC. Covered by: prnewswire.com |
#2 Pareto Securities Healthcare Conference: BioInvent believes that it has found the next big checkpoint in TNFR2 - this summer they had data both in solid and liquid tumors Published 2026-09-02 BioInvent reported BI-1808 data in ovarian cancer and CTCL, highlighted TNFR2 as a potential checkpoint, and expects NSCLC data for BI-1206 later this year. Covered by: biotechtv.com |
#3 K2 Therapeutics: Spreading bets across range of Asia-sourced assets Published 2026-09-03 K2 Therapeutics, led by former Legend CEO Ying Huang, is seeking a $250 million Series A to develop a diversified portfolio of Asia-sourced assets. Covered by: biocentury.com |
#4 Whitehawk Therapeutics to Participate in Upcoming Investor Conferences Published 2026-09-02 Whitehawk Therapeutics announced plans to participate in upcoming investor conferences. Covered by: prnewswire.com |
#5 Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals Published 2026-09-02 Novartis and Bristol Myers Squibb paused CAR-T trials over safety concerns, while Revolution Medicines gained early FDA approval for a pancreatic cancer drug and BioNTech halted an mRNA trial. Covered by: biospace.com |
#6 Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors Published 2026-09-02 Evotec and Plectonic will collaborate to evaluate Evotec’s CD2 bispecific platform alongside Plectonic’s logic-gated LOGIBODY DNA-protein immunotherapy for solid tumors. Covered by: prnewswire.com |
#7 Stock Watch: PD-1s, GLP-1s And Pharma Pairs Trading Published 2026-09-02 Andy Smith discusses life-science investing, focusing on PD-1 and GLP-1 drug markets and pairs-trading opportunities in pharmaceutical stocks. Covered by: insights.citeline.com |
#8 Pareto Securities Healthcare Conference: Mendus' cellular immunotherapy has been making progress in numerous cancers - being thoughtful about the setting and goal of treatment have been keys Published 2026-09-02 Mendus CEO Erik Manting discussed vididencel’s progress in AML, CML, and ovarian cancer, with additional CML data expected in the second half of the year. Covered by: biotechtv.com |
#9 Norroy Bioscience Initiates Pivotal Phase III Clinical Trial of 177Lu-NYM032, a PSMA-Targeted Radioligand Therapy for mCRPC Published 2026-09-02 Norroy Bioscience received China’s NMPA clearance to initiate a pivotal Phase III trial of 177Lu-NYM032 for metastatic castration-resistant prostate cancer. Covered by: prnewswire.com |
#10 Rigel All In On New Growth Driver, Veppanu, Licensed From Pfizer Published 2026-09-02 Rigel CEO Raul Rodriguez discussed licensing Pfizer’s breast cancer drug Veppanu, which Rigel expects to become its largest-selling product despite limited revenue potential for Pfizer. Covered by: insights.citeline.com |
